Odyssey Therapeutics, Inc. (ODTX)
Odyssey Therapeutics, Inc. (ODTX)
| Cash Flow | 2026-06-30 | 2026-03-31 |
|---|---|---|
| Net loss | -52,788 | -38,262 |
| Depreciation and amortization | 1,043 | 1,171 |
| Loss from disposal of property and equipment | -639 | 33 |
| Right-of-use asset impairment expense | 0 | 0 |
| Accretion of discount on marketable securities | -71 | 296 |
| Stock-based compensation expense | 5,671 | 2,587 |
| Non-cash rent expense | 878 | 879 |
| Change in fair value of contingent consideration and warrant liability | 8,804 | 109 |
| Prepaid expenses and other current assets | 1,591 | -3 |
| Other non-current assets | -1,469 | 1,686 |
| Accounts payable | -797 | 484 |
| Lease liabilities | -1,255 | -1,225 |
| Accrued expenses and other current liabilities | 3,348 | -4,766 |
| Net cash used in operating activities | -34,508 | -41,035 |
| Maturities of marketable securities | 34,950 | 34,950 |
| Purchases of marketable securities | 246,489 | - |
| Proceeds from sale of property and equipment | 281 | 0 |
| Purchases of property and equipment | 186 | 148 |
| Net cash (used in) provided by investing activities | -211,444 | 34,802 |
| Proceeds from the exercise of common stock options | 586 | 651 |
| Payment of deferred offering costs | - | 143 |
| Proceeds from the exercise of common stock warrants | 0 | - |
| Principal payments on finance leases | 46 | 24 |
| Proceeds from the issuance of common stock upon ipo, net of offering costs | 291,477 | - |
| Proceeds from the issuance of convertible preferred stock, net of issuance costs | 0 | - |
| Net cash provided by financing activities | 292,160 | 484 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 104 | 24 |
| Increase in cash, cash equivalents and restricted cash | 46,312 | -5,725 |
| Cash, cash equivalents and restricted cash, beginning of period | 39,172 | - |
| Cash, cash equivalents and restricted cash, end of period | 85,484 | 44,897 |
| Cash and cash equivalents, end of period | 82,031 | - |
| Restricted cash, included in other non-current assets, end of period | 3,453 | - |
| Total cash, cash equivalents and restricted cash, end of period | 85,484 | 39,172 |